Business

India Welcomes Wegovy: Is This ₹17,000/Month Weight Loss Shot the Real Deal?

Share

Novo Nordisk Launches Weekly Weight Loss Shot

Global healthcare giant Novo Nordisk has introduced its popular weight loss drug Wegovy in India. This weekly injection is now available for people struggling with obesity, bringing new momentum to the country’s expanding anti-obesity drug market.

What Is Wegovy?

Wegovy contains semaglutide, a compound that mimics a natural gut hormone. It helps curb appetite, regulate blood sugar, and slow digestion. While semaglutide is also found in diabetes medications like Ozempic and Rybelsus, Wegovy is designed specifically to help with weight loss in severely obese patients.

How Much Does It Cost in India?

Novo Nordisk has introduced tiered pricing based on dosage strength.
Here’s the breakdown:

  • 0.25 mg, 0.5 mg, 1 mg: ₹17,345 per month
  • 1.7 mg: ₹24,280 per month
  • 2.4 mg: ₹26,015 per month

The first three doses are priced equally to ease the transition for patients starting treatment.

Wegovy vs. Mounjaro: Which Works Better?

Mounjaro, made by Eli Lilly and already available in India, is Wegovy’s main competitor. It uses tirzepatide, a different compound with stronger weight loss effects.

In head-to-head trials:

  • 42.3% of Mounjaro users lost at least 15% of body weight
  • Only 18.1% of Wegovy users saw the same result
  • Average weight loss:
    • Mounjaro: 15.3%
    • Wegovy: 8.3%

Despite these numbers, Wegovy still offers valuable health benefits, especially for people with heart and liver issues.

Proven Health Benefits of Wegovy

Clinical trials show that Wegovy users may experience more than just weight loss:

  • 15% average body weight reduction
  • 1 in 3 lost up to 20% of their weight
  • 20% lower risk of heart attack or stroke
  • 19% reduction in all-cause mortality
  • 69% fewer heart failure events
  • 63% saw a reversal of liver fat build-up

These added benefits make Wegovy especially useful for patients with other chronic conditions.

Risks and Warnings to Consider

Doctors caution that Wegovy isn’t a magic fix. Some users lose muscle mass along with fat. Others may regain weight after stopping the drug. Medical supervision is essential during and after treatment.

India’s Growing Obesity Challenge

India is seeing a sharp rise in obesity, especially in urban areas. Experts urge that obesity be treated as a chronic medical condition, not just a lifestyle issue. The arrival of advanced treatments like Wegovy reflects a shift in how the disease is being addressed.

Wegovy brings a fresh option for weight loss to India’s healthcare landscape. With its weekly dose, proven health benefits, and focus on long-term management, it could be a game-changer for those who qualify. But like any prescription drug, it should be used carefully and under a doctor’s guidance.

image source

This post was published on June 25, 2025 2:42 pm

Recent Posts

Cheaper MacBook Air with iPhone Chip May Launch in 2026

Apple Reportedly Planning a cheaper MacBook Air with A18 Pro Chip : A more affordable MacBook Air may soon be…

18 minutes ago

Wordle July 1, 2025: Puzzle 1473 Hints and Answer Guide

Another Tricky Wordle? Puzzle #1473 May Test Your Streak : Wordle fans woke up today to tackle another brain-teasing challenge…

59 minutes ago

Extract Gold From Smartphone? Scientists Find A Safe Method

Extract gold from smartphone waste, it’s not just possible, it's becoming essential. As our devices age and get replaced, they're…

2 hours ago

Private Images to Train AI? Meta’s New Feature Raises Alarm

Private images to train AI are at the center of Meta’s latest privacy controversy. The tech giant, which owns Facebook…

2 hours ago

H1B Visa Now Allows Entrepreneurs to Self-Sponsor in US

In a historic change to US immigration policy, startup founders can now self-sponsor their own H1B visa. This update, launched…

3 hours ago

US Layoffs Hit 7 Lakh in Just 5 Months of 2025, BIG

Massive Surge in Layoffs Alarms American Workforce: Layoffs in the United States have skyrocketed in early 2025, with nearly 7…

3 hours ago